AI Stock Memo: DNLI - Denali Therapeutics - RankAlpha

DNLI

Rating buyAI Memo

Denali Therapeutics

As of 2026-02-26/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-02-26 • Model: RankAlpha Sentiment AI

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

buy

Confidence

medium

Horizon

—

Key catalyst

Clinical development milestone/readout • 2026-05-27

Expected move: +61%

Biggest risk

Clinical setbacks, tougher-than-expected competitive landscape, or funding dilution could drive the share price materially below the anchor; several analyst lows and revisions point to downside in adverse scenarios [#SERP-2].

Invalidation

Break below $18 or thesis failure.

What would change my mind?

Successful clinical readouts or a transformative partnership could validate Denali's pipeline and push valuation toward the high end of analyst ranges; upside supported by analyst highs (up to 50) and consensus averages above the current price [#SERP-5][#SERP-1].

Research note

Recommendation

buy

Confidence

medium

As of

2026-02-26

Base target

$32

p=60%

Bull target

$45

p=25%

Bear target

$18

p=15%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

12-month analyst re-rating window
Partnerships / late-stage progress impacting commercial optionality
Successful clinical readouts or a transformative partnership could validate Denali's pipeline and push valuation toward the high end of analyst ranges; upside supported by analyst highs (up to 50) and consensus averages above the current price [#SERP-5][#SERP-1].

BearKey bullets

Clinical trial failure or safety signal
Equity dilution to fund development
Unfavorable regulatory decisions or delays

WatchKey bullets

Clinical development milestone/readout

Summary

High-level snapshot

Recommendation

buy

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $32 (p=60%)

Bull/Bear spread: +131% / -8%

Vs latest close: Bull +131% · Base +61% · Bear -8%

Scenario probabilities

Bull Target: $45 (p=25%)Base Target: $32 (p=60%)Bear Target: $18 (p=15%)

Commentary

Market tone is cautiously constructive: analysts show a material upside bias with median/mean targets above the current price, while some firms maintain lower targets reflecting downside risk [#SERP-1][#SERP-6]. Newsflow and periodic analyst revisions are the main near-term drivers cited across sources [#SERP-5].

As of 2026-02-26 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

12-month analyst re-rating window
Partnerships / late-stage progress impacting commercial optionality

Human Analyst Targets

External snippets for comparison only; verify at source.

Unverified externalLast fetched 2026-02-26Source quality: external scrape

External snippets are unverified; treat as directional signals only. Always confirm with the original provider.

Inline RA est

Provider

serper

Median (USD)

$31.50

Range (USD)

$19.23 - $50.00

Count

Query: Denali Therapeutics Inc Common (DNLI) analyst consensus price target high low average

Denali Therapeutics (DNLI) Stock Forecast & Price Target
Search result #1
According to projections from 14 analysts, the average 12-month price target for Denali Therapeutics is 32.86 USD, with a high estimate of 40 USD and a low ...
Extracted: $32.86, $40.00Open source
Denali Therapeutics Inc.: Target Price Consensus and Analysts ...
Search result #2
UBS Adjusts Price Target on Denali Therapeutics to $25 From $24, Maintains Buy Rating · Wedbush Trims Price Target on Denali Therapeutics to $30 From $31, Keeps ...
Extracted: $25.00, $24.00, $30.00, $31.00Open source
Denali Therapeutics Inc. (DNLI) Stock Price, News, Quote & History
Search result #3
Analyst Price Targets. 25.00. 32.86 Average. 22.29 Current. 40.00 High. Analyst ... 0 Low. Sector Avg. 100 High. Research Reports: DNLI. View More. Daily ...
Open source
DNLI Stock Quote Price and Forecast - CNN
Search result #4
DNLI is trading near the top of its 52-week range and above its 200-day simple moving average. Price change. The price of DNLI shares has increased $0.57 since ...
Open source
Denali Therapeutics Inc Analyst Ratings - NASDAQ:DNLI - Benzinga
Search result #5
Denali Therapeutics Inc has a consensus price target of $33.89 based on the ratings of 22 analysts. The high is $50 issued by Evercore ISI Group on February ...
Extracted: $33.89, $50.00Open source
DNLI | Denali Therapeutics Inc. Analyst Estimates & Ratings – WSJ
Search result #6
Stock Price Target DNLI. High, $40.00. Median, $32.00. Low, $25.00. Average, $32.86. Current Price, $19.23. Related Links: Options · Overview · Research & ...
Extracted: $40.00, $32.00, $25.00, $32.86, $19.23Open source

Scenarios

Bull Target (Scenario probability)

$45 / p=25% prob

Base Target (Scenario probability)

$32 / p=60% prob

Bear Target (Scenario probability)

$18 / p=15% prob

Price $20 as of 2026-06-05

Nearest Scenario: Bear (∆ 8%)

Targets vs latest close: Bull +131% · Base +61% · Bear -8%

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-05-27
Clinical development milestone/readout
Potential mid-stage trial updates or program readouts for Denali's neurodegenerative pipeline could produce outsized moves; timing is uncertain so a conservative date (window end) is used in the absence of a disclosed date [#SERP-8].
Prob 30.00% • Move 50.00% • Priced-in 25.00%

Short-term Catalysts

Next few weeks

12-month analyst re-rating window
2026-05-27
Consensus analyst updates and model revisions over the next 12 months could re-rate the stock; consensus averages cited near 32.86 and median ~ 31.5 [#SERP-1][#SERP-6]. Conservative timing assumed to capture routine updates.
Prob 65% • Move 35% • Priced-in 40%

Long-term Catalysts

Months to a year

Partnerships / late-stage progress impacting commercial optionality
2027-02-26
Business-development deals or late-stage program progression could materially change long-term valuation; assumed out to one year (conservative) given limited public timing [#SERP-5].
Prob 20% • Move 60% • Priced-in 20%

Risks

Clinical trial failure or safety signal
Equity dilution to fund development
Unfavorable regulatory decisions or delays

Peers

Symbol	Summary
BIIB	Large-cap neuro specialist with commercial-stage neurology franchises; useful comparator for clinical/regulatory sensitivity.
IONS	RNA/antisense platform biotech with development-path overlap for CNS targets; useful for execution and partnership comparisons.
ACAD	Smaller CNS-focused company with commercial experience; illustrative peer for commercialization and market reception risk.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment AI
Human targets: serper
Targets query: Denali Therapeutics Inc Common (DNLI) analyst consensus price target high low average
Analysis date: 2026-02-26